AD_____

Award Number:
W81XWH-07-1-0208

TITLE:

How MMPs Impact Bone Responses to Metastatic Prostate Cancer

PRINCIPAL INVESTIGATOR:

Conor C. Lynch, PhD

CONTRACTING ORGANIZATION:

Vanderbilt University, Nashville, TN, 37232

REPORT DATE:

February 2010

TYPE OF REPORT:

 Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

    X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE *(DD-MM-YYYY)*	2. REPORT TYPE	3. DATES COVERED *(From - To)*
01-02-2010	Annual	01 FEB 2009 - 30 JAN 2010

4. TITLE AND SUBTITLE
How MMPs impact bone responses to metastatic prostate cancer

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-07-1-0208

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Conor C Lynch

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Vanderbilt University
Nashville TN, 37232

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
Using an animal model of prostate tumor progression in the bone we have previously shown that MMPs, namely MMP-2,-3,-9 and -13, are overexpressed at the tumor bone interface and these MMPs are for the most part expressed by the host cells of the bone. To test the contribution of MMPs in prostate tumor progression in the bone, we have generated mice that are immunocompromized and deficient for MMP-2,-3 and -9 during the current period. We have found that MMP-9 does not contribute to prostate tumor progression in the bone since no difference in osteolytic or osteoblastic responses between wild type and MMP-9 deficient animals were detected by Faxitron, CT, SPECT and histomorphometry. These results, while negative, are important for the generation of selective MMP inhibitors that lack the deleterious side effects associated with broad spectrum inhibitors. In addition, we have also identified PTHrP as an MMP substrate and postulate that MMP processing of PTHrP may be a mechanism through which MMPs can contribute to tumor induced osteolysis.

15. SUBJECT TERMS
Osteolysis, osteoblastic changes, prostate progression in bone, matrix metalloproteinases, MMPs, receptor activator of nuclear kappa B ligand, RANKL, bone metastasis.

16. SECURITY CLASSIFICATION OF: U			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	**b. ABSTRACT** U	**c. THIS PAGE** U	UU	19	**19b. TELEPHONE NUMBER** *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

Introduction……………………………………………….………..…..

This year, in the United States alone, of the 27,350 men who die from prostate cancer, 80% will have evidence of bone metastasis (1, 2). Prostate bone metastases cause several complications for patients such as hypercalcemia, spontaneous bone fracture and debilitating pain that dramatically affects their quality of life. To progress in the bone, the invading prostate tumor cells induce radical changes in bone matrix homeostasis by stimulating osteoblastic and osteolytic changes (3). These changes result in an actively remodeling bone tumor microenvironment, rich in mitogenic signals that promote tumor growth. In turn, the growth of the tumor exacerbates the osteoblastic and osteolytic changes in a manner that has been well described as the 'vicious cycle' (4). Using an animal model of

tumor progression in the bone, we have previously identified a group of enzymes known as matrix metalloproteinases (MMPs) as being highly overexpressed at the tumor bone interface in comparison to the tumor area alone. In a bid to understand the importance of these MMPs, namely MMP-2, -3, -9 and -13, in prostate tumor progression in the bone, we aim to generate MMP null animals and compare those animals to their wild type counterparts. While the MMPs are important in the turnover of the extracellular matrix, it has become apparent that the MMPs are also capable of regulating cell:cell communication by processing various cytokines and growth factors to active soluble forms (5). These soluble factors often influence biological processes including survival, proliferation, angiogenesis and osteoclast activation. Therefore, understanding which MMPs are important in contributing to prostate tumor progression in the bone and identifying the mechanisms that govern the vicious cycle can provide valuable targets for therapeutic development.

Body…………………………………………………………………………………………..

Accomplishments

Aim 1. *Determine the stromal contribution of MMPs that are markedly overexpressed at the tumor:bone interface namely, MMP-2,-3,-9 and -13 to prostate cancer induced osteoblastic and osteolytic changes in the bone.*

a) Generate immunocompromized RAG-2$^{-/-}$ mice that are deficient in MMP-2, MMP-3 and MMP-13 by crossing RAG-2$^{-/-}$ mice with MMP$^{-/-}$ mice that are both available on the C57Bl/6 background (Months 1-12).

b) Using our pre-clinical animal models, we will test the contribution of stromal MMP-9 to tumor induced osteoblastic and osteolytic change in readily available immunocompromized RAG-2$^{-/-}$ MMP-9 deficient mice (Months 1-12).

c) Test the contribution of stromal MMP-2, MMP-3 and MMP-13 to tumor induced osteoblastic and osteolytic change using our pre-clinical model (Months 11-30).

d) Identify the expression of stromal MMPs in human clinical samples of prostate bone metastases (Months 20-36).

The proposed animal model used in the study involved the transplantation of moderately differentiated rat prostate adenocarcinoma to the calvaria of immunocompromized wild type and MMP deficient mice. To achieve this, we crossed C57Bl/6 RAG-2 (recombinase activating gene-2) deficient mice with either C57Bl/6 MMP-2, -3 or -13 deficient animals in order to generate F2/F3 animals that are immunocompromized and deficient for the desired MMP. As of January 2010, we generated RAG-2$^{-/-}$;MMP-2$^{-/-}$, RAG-2$^{-/-}$;MMP-3$^{-/-}$ and RAG-2$^{-/-}$; MMP-13$^{-/-}$ animals and have made preliminary observations with these animals in terms of prostate tumor induced osteolytic and osteoblastic changes.

Host MMP-9 impacts angiogenesis in the prostate tumor-bone microenvironment but does not impact tumor induced osteolytic and/or osteoblastic changes.

In the initial 12 months of the project, we focused on assessing the impact of host derived MMP-9 in tumor induced osteolytic and osteoblastic changes. We observed that the cell responsible for bone destruction, the osteoclast, was the major cellular source of MMP-9 in the prostate tumor-bone microenvironment in our animal model. The clinical relevance of this observation was also tested. In collaboration with Dr. Bob Vessella, University of Washington (6, 7), we assessed the expression of

Fig. 1. Host MMP-9 does not contribute to prostate tumor induced osteolytic or osteoblastic changes. **A:** The amount of pathological bone (dashed line) was assessed in sections from WT (n=24) and MMP-9 deficient (n=37) animals at week 3. The number of osteoblasts generating pathological bone was also measured. **B:** The numbers of TRAP positive multinucleated osteoclasts (green) at the tumor bone interface (dashed line) in multiple sections revealed no difference in numbers between the WT and MMP-9 deficient groups. DAPI (blue) was used as a nuclear stain. No differences in the bone destruction indices were observed. Arrows indicate areas of osteolysis.

MMP-9 in 10 human samples of prostate to bone metastasis and observed that again, osteoclasts were a major cellular source of MMP-9 in the **human** prostate tumor-bone microenvironment. To test whether host MMP-9 contributed to prostate tumor induced osteolysis or osteogenesis, we utilized immunocompromized animals that were either wild type or null for host MMP-9. In repeated studies, with at least 10 animals per group, we determined that MMP-9 does not have any effect on tumor progression in the bone using both whole animal imaging modalities such as microCT and microSPECT and traditional histomorphometry approaches. While there was a trend towards a decrease in osteolysis in the MMP-9 deficient animals,

Fig. 2. Osteoclast derived MMP-9 regulates VEGF-A$_{164}$ bioavailability and angiogenesis. A, Representative photomicrographs of mature multinucleated osteoclasts generated from CD11b^{+ve} myeloid precursor cells isolated from WT or MMP-9$^{-/-}$ mice after 10 days of culture in osteoclast differentiation media. Scale bars represent 50μm. B, Quantitation of the number of osteoclasts generated by treatment with control or osteoclast (OCL) differentiation media. Only multinucleated (>3/cell) TRAcP positive cells were counted. C, Quantitation of VEGF-A$_{164}$ levels in conditioned media derived from WT or MMP-9$^{-/-}$ osteoclast (OCL) cultures in the presence or absence of 100ng/ml recombinant MMP-9. D, Representative photomicrographs of mouse thoracic aortas stimulated with WT or MMP-9$^{-/-}$ osteoclast culture conditioned media (CM) at day 7. The average distance of sprout migration was calculated from photomicrographs on a daily basis. Scale bar represents 1mm. n.s. denotes non-significant (p>0.05) p values. * denotes p<0.05, ** denotes that p<0.01, *** denotes that p<0.001.

this decrease did not prove to be statistically significant (Figure 1). While these data suggest that MMP-9 does not contribute to tumor progression in the bone, it should be stated that the role of MMP-9 in 1) the metastasis of prostate cancer to the bone or 2) in the initial survival/establishment of the prostate tumor cells in the bone microenvironment can not be ruled out since these steps are not recapitulated in our animal model. Previous studies have shown that MMP-9 is important in mediating angiogenesis in the tumor microenvironment (8) and using the endothelial antigen CD-31 as a marker for angiogenesis, we found decreased angiogenesis in the MMP-9 null group. In follow-up experiments we identified that while MMP-9 did not impact the ability of myeloid cells to become

mature multi-nucleated osteoclasts, there was a significant decrease in the ability of the MMP-9 null osteoclasts to mediate the bioavailability of the potent angiogenic factor vascular endothelial growth factor A (VEGF-A$_{164}$) (Figure 2). This observation explains, in part, the reduced vascularity of the tumors in the MMP-9 null animals. These results therefore demonstrate that while host, specifically osteoclast derived MMP-9, does not contribute to tumor induced osteolysis and osteogenesis, it does contribute to angiogenesis in the tumor-bone microenvironment. Furthermore, our results resonate with emerging studies from other groups that establish the osteoclast as an angiogenic cell (9, 10). These data have recently been reported in the journal *Molecular Cancer Research* (11).

Host MMP-13 has a protective role in the prostate tumor-bone microenvironment

Murine MMP-13 is considered to be the ortholog of human MMP-1, and MMP-13 deficient animals have been reported as having a delay in endochondral ossification during skeletal development with thickened trabecular bone persisting in the animals (12, 13). In collaboration with Dr. Stephen Krane, we generated immunocompromized MMP-13 deficient mice. Histological analysis of the calvaria from these animals at 6 weeks of age and their age matched wild type counterparts were similar with respect to the amount of bone and number of osteoclasts (data not shown). Surprisingly, preliminary studies using our animal model suggested that host MMP-13 plays a protective role in preventing tumor

Fig. 3. MMP-13 has a protective role in prostate tumor induced osteoblastic and osteolytic changes. **A:** The number of osteoblasts and the amount of pathological bone in multiple sections (10x fields) were calculated in MMP-13 (n=7) and wild type mice (n=5). **B:** The number of TRAP stained (red) multinucleated osteoclasts (arrows) per field in addition to the to the bone destruction index in multiple sections were also calculated. Asterisk denotes statistical significance with p<0.05.

induced osteolytic and osteoblastic changes (Figure 2). At three weeks post implantation,

immunocompromized wild type and MMP-13 deficient animals were sacrificed. Histological analysis revealed that in comparison to wild type controls, MMP-13 deficient sections had higher numbers of osteoblasts and osteoclasts which was consistent with increase bone formation and destruction respectively. These data are unexpected since MMP-13 has been described as the rate limiting collagenase for murine skeletal development. These data suggested that in the pathological context of the tumor bone microenvironment, *host MMP-13 inhibits the vicious cycle and plays a protective role in the tumor-bone microenvironment.* The concept of MMPs as playing a protective role during tumor progression has been reported for MMP-3 and MMP-8 during skin carcinogenesis and progression in mice but to our knowledge MMP-13 has not been described as being protective in a pathological context (14, 15). These studies have been repeated and we are currently exploring the mechanisms through which MMP-13 protects against prostate tumor progression in the bone.

Our collected data illustrated that MMP-7, -9 and -13 are highly expressed in the prostate tumor-bone microenvironment but on an individual basis, they clearly play very different roles with respect to tumor induced osteoblastic and osteolytic changes. In the final year of the proposal, we have also observed that host MMP-2 significantly impacts the progression of tumors in the bone microenvironment while host MMP-3 appears to play a limited role upon gross observations. Our currently research is focused on identifying how MMP-2 and MMP-13 can contribute to/or protect against prostate tumor progression in the bone microenvironment using our animal model. We anticipate that the results of these studies will be published within the next 12 months.

Conclusions from Aim 1. Initially we set out to test whether individual host MMPs contributed to prostate tumor progression in bone using a unique animal model. Our results and preliminary findings show that in some cases, individual MMPs can contribute (MMP-7 and MMP-2) while others can be protective (MMP-13) or play more subtle roles (MMP-9). These findings support the conclusions drawn from human clinical trials with MMP inhibitors that stated in order to avoid the deleterious side effects of broad spectrum MMP inhibitors, the roles for individual MMPs needed to be elucidated so

that more selective therapeutics could be generated. The data collected during this grant highlights the individual roles that MMPs can play in the prostate tumor-bone microenvironment and provides a shortlist of MMPs (MMP-2, MMP-7 and MMP-9) that could be therapeutically targeted for the treatment of prostate to bone metastases.

Aim 2. *Identify and test MMP processed substrates that mediate prostate tumor induced osteolytic and osteoblastic change.*

    a) Identify and test candidate MMP substrates that mediate prostate tumor induced osteolytic and osteoblastic change.

    b) Determine the contribution of MMP solubilized RANKL vs. MMP resistant RANKL in mediating osteoclastogenesis

In aim 2, we took a candidate approach in a bid to identify the potential factors that MMPs process in order to mediate tumor induced osteolysis. Bone is a rich reservoir of growth factors such as transforming growth factorβ (TGFβ) and insulin like growth factor-1 (IGF-1) and both of these factors have been implicated in driving the 'vicious cycle' (4). Given that various MMPs have been reported as processing the molecules that keep these growth factors in a latent state such as latency TGFβ binding proteins (LTBPs) and IGF binding proteins (IGF-BPs) we envisaged that these would be excellent candidate molecules through which MMPs could contribute to osteolytic and osteoblastic changes in the bone microenvironment.

MMP-2 is a key regulator of TGFβ bioavailability

In our initial studies, we examined the presence of active TGFβ using ELISA techniques. While we observed that there is more active TGFβ at the tumor bone interface in comparison to the tumor area alone, we found no difference in the levels of active TGFβ between wild type, MMP-7 and MMP-9 null animals (Figure 4). Given the labile nature of TGFβ we have taken multiple approaches into

identifying the activity status of the cytokine in wild type and MMP null animals. Using procedures described by Barcellos-Hoff et al.(16), we generated frozen sections of non-decalcified bone using the Cryo-Jane Tape transfer system. The approach allowed us to visualize latent and active TGFβ and the effectors of TGFβ such as phospho SMAD2 in the tumor-bone microenvironment using microscopy (Figure 4).

In parallel studies, we localized the major cellular sources of the MMPs under investigation in human and murine tumor-bone microenvironments. Surprisingly, we identified that osteoblasts and osteocytes are major sources of MMP-2. In Specific aim 1, our initial studies revealed that host MMP-2 contributed to tumor progression in the bone microenvironment. Thus far we have not generated enough animals to test whether differences in the levels of active TGFβ exist between the wild type and MMP-2 null immunocompromized animals. Therefore, in order to test if osteoblast derived MMP-2 is regulating the bioavailability of TGFβ we isolated primary osteoblast cultures from immunocompetent MMP null animals and tested the ability of the MMP null osteoblasts to produce active TGFβ *in vitro*. Our initial experiments have provided exciting results. We have identified that osteoblast derived MMP-2 plays a major role in facilitating TGFβ activation and for first time have shown that LTBP-3 which is predominantly expressed in the skeleton is a major player in this process. In our

Fig. 4. TGFβ activation in the tumor bone microenvironment. **A:** The levels of TGFβ in lysates of the calvarial prostate tumor-bone interface and tumor area alone were measured by ELISA in WT and MMP-7, MMP-9 null mice. Asterisk denotes statistical significance (p<0.05). n.s. denotes non-significance. **C:** ELISA of active TGFβ in WT and MMP-2 null conditioned media (CM) derived from primary osteoblasts (n≥4 primary cultures per group). Samples were normalized for total protein. Recombinant MMP-2 (rMMP-2; 20ng/ml for 3 hours at 37°C) was also added to osteoblast CM and TGFβ activation was assessed. Asterisk denotes p<0.05. ANOVA analysis followed by a Tukey comparison of all conditions revealed that rMMP-2 addition enhanced TGFβ activation. Double asterisk denotes p<0.01, triple asterisk denotes p<0.001). **D:** WT osteoblast CM was incubated with 50ng of rMMP-2 overnight or 1µg of plasmin. Western blot analysis for LTBP-3 shows processing of full length LTBP-3 (arrow head) to a lower molecular weight form (arrow) presumably resulting in the activation of TGFβ. **E:** Immunofluorescent detection of active TGFβ at the tumor bone interface (red; arrows) in frozen sections. Dashed line indicates tumor bone interface while arrow head indicates TRAcP positive (green) multinucleated (DAPI;blue) mature osteoclasts. **F:** pSMAD-2 (arrow head; brown), a down stream effector of TGFβ signaling, was detected in cancer cells proximal to the tumor bone interface.

preliminary observations, we have found that osteoblast derived MMP-2 contributes to tumor progression in the bone microenvironment and that the regulation of TGFβ bioavailability is the major

molecular mechanism underlying this phenomenon (Figure 4). We are currently repeating these experiments using our animal model system but are also using other models in order to test the role of osteoblast derived MMP-2 in tumor progression in the bone microenvironment. We anticipate that the findings of these studies will be published by the end of 2010.

PTHrP is a novel MMP substrate

In the metastatic bone:tumor microenvironment, parathyroid related hormone (PTHrP) has been identified as a powerful mediator of osteolysis (17). Pro-PTHrP has three isoforms that are 139, 141 or 173 amino acids in length. These isoforms are subsequently enzymatically processed to yield the mature form of PTHrP$_{1-36}$ (amino acids 1-36). Thus far the enzymes implicated in generating mature PTHrP have been; endothelin converting enzyme-1 (ECE-1); ECE-2 and neprilysin which are not MMPs but are members of the metazincin family of proteinases. Interestingly, prostate specific antigen (PSA) which is a serine protease has also been shown to process PTHrP but in a different region that generates a 23 amino acid form of PTHrP$_{1-23}$ (18). This is thought to abolish the activity of the hormone but some studies suggest that smaller molecular weight versions of PTHrP can have differential effects compared to PTHrP$_{1-36}$ (19).

Fig. 5. PTHrP is an MMP substrate. **A:** RT-PCR analysis of PTHrP expression by the prostate cancer tissue (PLSP). +ve refers to positive control. **B:** Mature PTHrP (100ng; arrow head) was incubated for 1 hour at 37°C either alone or with 100ng of active MMP-3. Arrow indicates cleavage product. Markers are in kDa. **C:** Immunoblot analysis also demonstrates PTHrP processing using an antibody directed to the C-terminus (Santa Cruz; sc-20728). **D:** N-terminal amino acid sequencing revealed that MMP-3 generated PTHrP$_{1-36}$. **F.** MALDITOF-MS showed that MMP-3 was capable of further processing of PTHrP$_{1-36}$. Similar analyses revealed no degradation of full length PTHrP in the absence of MMPs. **E-F:** MC3T3-E1 (10^5 cells per 6 well in triplicate) were incubated with 50nM PTHrP$_{1-36}$ or equimolar concentrations of PTHrP fragments corresponding to MMP-3 products. No difference in mineralization was determined by day 21 using alizarin red and spectrophotometry (E). However, treatment with PTHrP$_{1-16}$ significantly stimulated MC3T3 cell growth as assessed by MTT assay (F).

Since PTHrP can be processed by members of the metazincin family and given the presence of MMPs in the tumor bone microenvironment, we asked whether MMPs could process PTHrP. Using recombinant PTHrP$_{1-141}$, we observed that MMP-3 and MMP-7 generate mature PTHrP$_{1-36}$ (Figure 5). Further examination by mass spectroscopy revealed that MMP-3 and MMP-7 further processed PTHrP$_{1-36}$ into smaller fragments, namely PTHrP$_{1-16}$, PTHrP$_{17-26}$ and PTHrP$_{27-34}$. A number of the MMP generated PTHrP products have reported cellular functions. For example, PTHrP$_{1-16}$ has sequence similarities to endothelin-1 (ET-1). ET-1 has been identified as a major factor involved in promoting osteoblastic responses via the ET$_A$ receptor (20). PTHrP$_{1-16}$ has been shown to bind to ET$_A$ in cardiomyocytes but apparently has no impact on ET$_A$ signaling when overexpressed in CHO cells (21, 22). However, the precise role of PTHrP$_{1-16}$ in osteoblast function is unclear. Other MMP-3 generated fragments such as PTHrP$_{27-36}$ can mediate protein kinase C signaling via the PTHR-1 receptor (23) but again, the precise role of this fragment in addition to PTHrP$_{17-26}$ in osteoblast function remain unclear. Our initial experiments identified that the MMP generated fragments can impact the behavior of the osteoblasts with respect to growth but it does not appear that the fragments impact osteoblast differentiation and invasion. We are currently further assessing the in vitro and in vivo relevance of the MMP generated PTHrP products and they will be the focus of future studies.

MMPs generate an active soluble form of RANKL.
We have previously demonstrated that membrane bound receptor activator of nuclear κB ligand (RANKL) which is essential for osteoclast maturation and activation is sensitive to shedding from the cell surface by MMP-3 and MMP-7 (24) and have found that the mechanism is not only

Fig. 6. A: MMP-7 processes RANKL in the juxtamembrane region at amino acid position 142 (see figure 10 for additional information). To generate a non-cleavable mutant RANKL, the methionines at positions 142 and 143 in addition to the proline at position 140 were mutated by single nucleotide substitution using a site directed mutagenesis kit (Stratagene). Methionine to Valine (ATG to GTG) and Proline to Leucine (CCA to CTA) **B:** Wild type and Δ-RANKL full length cDNAs were in vitro translated using the Promega TnT *in vitro* translation system with S^{35} labeled methionine. **1:** Δ-RANKL alone. **2-3:** Δ-RANKL(2) or wild type RANKL(3) incubated with 100ng of MMP-7 overnight at 37°C. Arrow indicates full length unglycosylated Δ-RANKL at approx 40kDa. Arrow heads denote cleavage products.

relevant in the prostate tumor-bone microenvironment but also in the breast (25). Experiments in this

study have resulted in the generation of non-cleavable of RANKL and future studies are focused on testing the ability of the non-cleaved RANKL to stimulate osteoclast activation via direct cell:cell contact and generating knock in animals (Figure 6).

Conclusions from Aim 2

Using a candidate approach we have found that MMPs that are highly expressed in the tumor-bone microenvironment (MMP-2, -3, -7) can process the factors that drive the vicious cycle. MMPs have primarily been considered as playing important roles in matrix degradation and while this may be true, clearly they are also playing key roles in regulating the availability and bioactivity of key factors such as PTHrP, RANKL and TGFβ. These discoveries have several innovations and highlight potential areas for therapeutic targeting.

Key Research Accomplishments……………………………………….……..

- Generated RAG-2;MMP-2, RAG-2;MMP3, RAG-2;MMP-13 null animals
- Identified osteoclasts as a major source of MMP-9 in the human and murine prostate tumor-bone microenvironments
- Demonstrated that host derived MMP-9 does not contribute to tumor progression in the bone but does impact angiogenesis
- Determined that host MMP-13 plays a protective role in preventing tumor induced osteolytic and osteoblastic changes
- Identified that host MMP-2 contributes to tumor progression in the bone microenvironment
- Identified higher levels of TGFβ at the tumor bone interface in comparison to the tumor area alone in wild type animals
- Identified that osteoblast derived MMP-2 is a major regulator of TGFβ bioavailability
- Identified that MMP-3 and MMP-7 are capable of generating mature PTHrP
- Identified that MMP generated PTHrP fragments impact osteoblast behavior

- Generated a non-cleavable version of RANKL

Reportable Outcomes…………………………………………………………………

Manuscripts

1) Bruni-Cardoso A, Johnson LC, Peterson TE, Vessella RL and **Lynch CC**. (2010). Osteoclast MMP-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol. Cancer Res. 8 (4) April issue. In press.

2) Fowler JA, Mundy, GR, Lwin ST, **Lynch CC** and Edwards CM (2009). A murine model of myeloma that allows genetic manipulation of the host microenvironment. Disease Models and Mechanisms. Nov-Dec;2(11-12):604-11. PMCID: PMC2776114

3) Thiolloy S, Halpern JL, Holt GE, Schwartz HE, Mundy GR, Matrisian LM and **Lynch CC**. (2009). Host derived MMP-7, but not MMP-9 impacts mammary tumor induced osteolysis. Cancer Res. August 15, 69:6747-55.

Book Chapters

1) Lynch CC and Matrisian LM (2008). Matrix metalloproteinases as key regulators of tumor-bone interaction. The Cancer Degradome, Proteases and Cancer Biology. Edwards DR, Hoyer-Hansen G, Blasi F and Sloane BF (Eds). Springer, NY. Chapter 27, p541-566

2) Mundy GR, Edwards CM, Edwards JR, Lynch CC, Sterling JA and Zhuang J. (2008). Localized Osteolysis. Principals of Bone Biology. (3rd Edition) Biezikian J, Craig Z, Martin TJ (Eds) Academic Press, Inc., San Diego, CA. Chapter 64, p1391-1413.

3) Fingleton B and Lynch CC (2009). Cancer in context: The importance of the tumor microenvironment. Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi A (Eds). Springer, NT, Chapter 3, p75-100.

Presentations

Tumor Microenvironment Steering Committee Meeting, Nashville, TN, 2009.

Cancer And Bone Society, Arlington, VA. October, 2009.

Gordon Research Conference-Matrix Metalloproteinases, Les Dialebtres, Switzerland, August 2009.

Growth Factor and Signaling Symposium, Ames, Iowa, September, 2008

Joint AACR and Metastasis Research Society Meeting, Vancouver, BC, Canada, August, 2008

Tumor host interaction and angiogenesis meeting, Monte Verita, Ascona, Switzerland, October 2007.

Tumor microenvironment (TMEN) meeting, Vanderbilt University, Nashville, TN, September, 2007.

Grants

NCI-(1RO1CA143094-01A1).   01-JUL-10-30-JUN-15.

Role: Principal Investigator.

Title: Host MMP-mediated regulation of the vicious cycle of prostate to bone metastases

Overall Conclusions………………………………………………………………………………

Our results have shown that individual MMPs can have differential effects in the tumor-bone microenvironment. Previously, MMP inhibitors failed in the clinical setting, primarily due to a lack of understanding as to how MMPs contribute to tumor progression. In animals models of osteolysis, broad spectrum MMP inhibitors have been successful in preventing tumor induced osteolysis and growth (26-28). Therefore, in order to apply MMP inhibitors in the clinical setting, our results suggest that the selective targeting of MMP-2, MMP-7 and MMP-9 while sparing the activity of other metalloproteinase family members such as MMP-13 would be of benefit for the treatment of prostate to bone metastases. Finally, as a new investigator award mechanism, this grant from the DOD has been essential in allowing me to become an independent and established investigator. Based on my results acquired from this application, I have been able to generate an National Cancer Institute RO1 proposal that recently scored in the 12th percentile and is highly likely to be funded beginning July 1st,

2010. Therefore, I am extremely grateful for the DOD in allowing me this opportunity to kick start my career in identifying cures for prostate to bone metastases.

References…………………………………………………………………….

1.   www.cancer.org. Cancer Facts and Figures. American Cancer Society 2008.

2.   Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 2000; 31: 578-83.

3.   Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry 2004; 91: 718-29.

4.   Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2002; 2: 584-93.

5.   Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561-73.

6.   Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008; 180: 1154-60.

7.   Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20: 171-80.

8.   Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000; 2: 737-44.

9.   Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008; 14: 6387-95.

10.   Cackowski FC, Roodman GD. Perspective on the osteoclast: an angiogenic cell? Ann N Y Acad Sci 2007; 1117: 12-25.

11.   Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Osteoclast-Derived Matrix Metalloproteinase-9 Directly Affects Angiogenesis in the Prostate Tumor-Bone Microenvironment. Mol Cancer Res 2010.

12.   Inada M, Wang Y, Byrne MH, et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 17192-7.

13.   Stickens D, Behonick DJ, Ortega N, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice 2. Development 2004; 131: 5883-95.

14.   Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35: 252-7.

15.   McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004; 64: 6965-72.

16.   Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994; 93: 892-9.

17.   Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88: 2892-8.

18.   Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-31.

19.   Ruchon AF, Marcinkiewicz M, Ellefsen K, et al. Cellular localization of neprilysin in mouse bone tissue and putative role in hydrolysis of osteogenic peptides. J Bone Miner Res 2000; 15: 1266-74.

20.   Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003; 100: 10954-9.

21.   Langlois C, Letourneau M, Turcotte K, Detheux M, Fournier A. PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors. Peptides 2005; 26: 1436-40.

22.   Schluter KD, Katzer C, Piper HM. A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol 2001; 132: 427-32.

23.   Miao D, Tong XK, Chan GK, Panda D, McPherson PS, Goltzman D. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 2001; 276: 32204-13.

24.   Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL 1. Cancer Cell 2005; 7: 485-96.

25.   Thiolloy S, Halpern J, Holt GE, et al. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res 2009; 69: 6747-55.

26.   Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. European Journal of Cancer 2001; 37: 106-13.

27.   Winding B, NicAmhlaoibh R, Misander H, et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clinical Cancer Research 2002; 8: 1932-9.

28.   Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. Journal National Cancer Institute 2002; 94: 17-25.